Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | -2.0x | ||
| Revenue | 24.375 M | ||
| Net Income to Company | -53.949 M |
| ELUT | Peers | Sector | |
|---|---|---|---|
Market Cap | 110.4 M | 182.9 M | 62.454 M |
Price % of 52 Week High | 51.7% | 46.8% | 61.1% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -23.5% | -12.3% | -0.7% |
1 Year Price Total Return | -12.3% | -47.0% | -13.2% |
Beta (5 Year) | 0.96 | 1.33 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 24 | 25 | 24 | 5.88 | 5.47 |
| Operating Income | (30) | (21) | (24) | (5.80) | (5.82) |
| Net Profit | (33) | (38) | (54) | (9.31) | (9.06) |
| Diluted EPS | -2.62 | -2.27 | -1.86 | -0.69 | -0.26 |
| EBITDA | (26) | (17) | (21) | (5.14) | (4.96) |
| Balance Sheet | |||||
| Cash & ST Invest. | 17 | 19 | 13 | 19 | 13 |
| Current Assets | 51 | 31 | 26 | 31 | 26 |
| Total Assets | 69 | 43 | 36 | 43 | 36 |
| Current Liabilities | 43 | 43 | 38 | 43 | 38 |
| Total Liabilities | 74 | 82 | 82 | 82 | 82 |
| Total Equity | (5.03) | (39) | (46) | (39) | (46) |
| Total Debt | 24 | 24 | 25 | 24 | 25 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (21) | (22) | (23) | (9.08) | (12) |
| Cash From Investing | (0.54) | 14 | (0.47) | 15 | (0.09) |
| Cash From Financing | 8.54 | 9.84 | 17 | (0.69) | (0.15) |
| Free Cash Flow | (22) | (22) | (23) | (9.10) | (12) |